Depo-Provera Lawsuit 2026: Critical Daubert Hearing Could Define 3,790 Cases

My name is Mason Arnao, and my background in data systems, technology infrastructure, and digital advocacy has given me a deep understanding of how the Depo-Provera lawsuit 2026 affects real people navigating complex legal and medical systems. As publisher of TortAdvisor.com and President of Waypoint Software, I’ve spent over 20 years building systems that connect people with critical information. In this guide, I’ll break down everything you need to know to understand your rights and take action.

The Depo-Provera lawsuit 2026 has reached a critical inflection point. With over 3,790 plaintiffs now consolidated in MDL 3140 in the Southern District of New York, federal judges are preparing to hear Daubert challenges that could reshape the entire litigation. Women who were diagnosed with meningioma brain tumors after receiving Depo-Provera (medroxyprogesterone acetate) injections are asserting that Pfizer and its subsidiary Pharmacia failed to adequately warn them of this devastating risk — despite decades of scientific evidence linking synthetic progestins to meningioma growth. If you or a loved one received Depo-Provera injections and later developed a meningioma, you may be entitled to significant financial compensation. This guide covers the latest 2026 developments, who qualifies, and how to protect your legal rights before the statute of limitations expires.

Depo-Provera Lawsuit 2026: Latest Daubert Hearing Updates

The Depo-Provera lawsuit 2026 is entering one of its most consequential phases. In MDL 3140, presiding Judge Mary Kay Vyskocil has scheduled a series of Daubert hearings — the gatekeeping procedure by which federal courts determine whether expert scientific testimony meets the standards necessary to go before a jury. The outcome of these hearings will be decisive: if plaintiffs’ experts survive Daubert challenges, Pfizer faces the real prospect of bellwether trials before the end of 2026.

The scientific basis for the Depo-Provera meningioma link has grown substantially over the past several years. A landmark 2024 study published in the British Medical Journal found that women who used injectable progestogen contraceptives — including Depo-Provera — had a significantly elevated risk of developing intracranial meningiomas compared to non-users. This study, which analyzed data from over 100,000 women, is expected to serve as the cornerstone of plaintiffs’ expert causation arguments. According to research published on the National Institutes of Health, meningiomas are the most common type of primary brain tumor, and hormonal factors — particularly progestin exposure — are increasingly recognized as significant risk factors.

Pfizer’s defense strategy has centered on challenging the strength of the epidemiological evidence, arguing that the BMJ study and others relied upon by plaintiffs contain methodological flaws. Defense attorneys have sought to exclude multiple plaintiff experts on grounds that their causation opinions do not satisfy the Daubert standard of reliability. Plaintiffs’ attorneys counter that decades of peer-reviewed research — including studies from the FDA and academic medical centers — establish a biologically plausible and statistically significant link that well exceeds Daubert requirements.

The stakes could not be higher. If plaintiffs prevail on Daubert, bellwether trials — cases specifically selected to test litigation theories against a jury — are likely to begin in late 2026 or early 2027. Verdicts in those cases will form the template for a global settlement that could be worth billions of dollars. Legal analysts following the MDL docket on CourtListener have noted the unusually large case filings, suggesting both sides are prepared for a protracted fight.

In February 2026, Pfizer filed updated Daubert motions targeting the general causation opinions of three leading plaintiff experts, including a neuro-oncologist, an epidemiologist, and a pharmacologist. Plaintiffs filed comprehensive opposition briefs in March 2026 supported by over 400 pages of scientific literature. The court is expected to issue rulings by summer 2026, with any trial date contingent on those decisions.

Meanwhile, case filings continue to surge. Attorneys across the country are signing up women who received Depo-Provera injections over extended periods — particularly those who used it for five or more years — and who subsequently developed meningiomas requiring surgery, radiation, or other serious intervention. The average severity of injuries in this MDL is high, and legal experts believe per-case settlements could reach seven figures for the most serious cases.

What Is a Meningioma and How Does Depo-Provera Cause It?

To understand the Depo-Provera lawsuit, it is essential to understand the injury at its center: meningioma. A meningioma is a tumor that arises from the meninges — the three layers of protective membranes that surround the brain and spinal cord. While most meningiomas are benign (non-cancerous), they are far from harmless. As these tumors grow, they press against the brain and other vital structures, causing symptoms that can be debilitating and life-altering.

Common meningioma symptoms include severe and persistent headaches, vision problems (blurring, double vision, or loss of peripheral vision), hearing loss or ringing in the ears, memory problems and cognitive impairment, weakness or numbness in the arms or legs, seizures, and in some cases, personality changes and depression. Many patients require brain surgery — a craniotomy — to remove the tumor, followed by radiation therapy to prevent recurrence. Recovery can take months to years, and some patients experience permanent neurological deficits.

The mechanism linking Depo-Provera to meningioma growth is increasingly well understood. Meningiomas express progesterone receptors, meaning they are hormonally sensitive tumors. Depo-Provera’s active ingredient, medroxyprogesterone acetate (MPA), is a synthetic progestin that binds to these receptors and can stimulate tumor growth. The longer a woman uses Depo-Provera, and the higher the cumulative dose, the greater the potential for meningioma development or accelerated growth.

Research published in peer-reviewed journals has consistently found elevated meningioma risk in women who use high-dose progestins. The 2024 BMJ study was particularly significant because it specifically examined injectable progestins — the delivery method used by Depo-Provera — and found the elevated risk was most pronounced for women who used the injection for more than five years. Critics of Pfizer argue that the company knew or should have known about this risk for decades and failed to include adequate warnings in Depo-Provera’s prescribing information.

The FDA has not issued a specific formal warning linking Depo-Provera to meningioma as of the time of this writing, though agency communications and the broader regulatory landscape suggest that scrutiny of progestin-meningioma links has intensified significantly. Plaintiffs argue that Pfizer had an obligation to update their label proactively as scientific evidence accumulated — an obligation they allegedly failed to meet. You can review the FDA’s Depo-Provera safety communications for more background on the regulatory history of this drug.

For women diagnosed with meningioma after using Depo-Provera, the emotional and financial toll is enormous. Many describe undergoing terrifying brain surgeries without knowing that the contraceptive they trusted for years may have been the cause. The Depo-Provera lawsuit represents an opportunity for these women to hold Pfizer accountable and receive the compensation they deserve for their pain, medical expenses, lost wages, and diminished quality of life.

Who Qualifies for the Depo-Provera Lawsuit?

If you received Depo-Provera (medroxyprogesterone acetate) injections and later developed a meningioma, you may be eligible to join the Depo-Provera lawsuit 2026. Eligibility criteria are based on the nature of your Depo-Provera use and your diagnosis. Below is the general qualification checklist that attorneys use when evaluating cases:

• You received Depo-Provera injections — typically administered every three months (the standard 150mg/mL dosing schedule)
• Duration of use was significant — most cases involve use of one year or more, with stronger cases involving three or more years of use
• You were diagnosed with a meningioma — confirmed by MRI, CT scan, biopsy, or surgical pathology report
• Your meningioma diagnosis came after Depo-Provera use — or the tumor was found to have grown or progressed during your use of the drug
• Your meningioma required medical treatment — including watchful waiting with documented symptoms, surgery, radiation therapy (stereotactic radiosurgery or external beam), or a combination
• You are within the statute of limitations — deadlines vary by state, but most give victims 2-3 years from the date they discovered or should have discovered the connection between Depo-Provera and their meningioma
• You are a U.S. resident — MDL 3140 covers claims filed in U.S. federal courts

Cases involving more severe meningiomas — those that required surgery, caused permanent neurological damage, or significantly impacted quality of life — are generally assigned higher settlement values. If you are uncertain whether you qualify, the best step is to call 1 (855) 664-8713 for a free, confidential case evaluation. Our team can review your Depo-Provera usage history and medical records to determine whether you have a viable claim.

It is also worth noting that family members of deceased victims may be able to file wrongful death claims in certain circumstances. If your loved one passed away from complications related to a meningioma that developed after Depo-Provera use, you may still be able to pursue compensation on their behalf. An attorney can advise you on the specific laws in your state.

Depo-Provera Settlement Amounts: What You Can Recover

While no global settlement has been reached in the Depo-Provera MDL as of May 2026, legal analysts and mass tort attorneys have developed preliminary valuations based on comparable drug litigation. The Depo-Provera settlement calculator on TortAdvisor can help you estimate the potential value of your claim, but here is a general framework based on injury severity:

Tier 1 — Severe Injury (Est. $750,000 – $1,500,000+): Cases in this tier involve meningiomas that required craniotomy or significant surgical intervention, caused permanent neurological deficits (vision loss, hearing loss, cognitive impairment, weakness), required radiation therapy, or significantly diminished quality of life. Cases involving very long-term Depo-Provera use (5+ years) and large or multiply recurrent tumors are also likely to fall in this tier.

Tier 2 — Moderate Injury (Est. $250,000 – $750,000): This tier includes cases where the meningioma required surgery or other significant treatment but recovery was largely successful, or where the tumor is being monitored with watchful waiting and has caused documented symptoms that affect daily functioning. Moderate-term Depo-Provera use (2–5 years) combined with treatment-requiring meningiomas would typically fall here.

Tier 3 — Less Severe Injury (Est. $50,000 – $250,000): Cases where the meningioma was discovered incidentally, requires watchful waiting only, and has not yet caused significant symptoms may fall into this tier. Short-term Depo-Provera use combined with asymptomatic or minimally symptomatic tumors would also be evaluated in this range.

These are preliminary estimates only. Actual settlement values will depend on many factors, including your specific medical history, the strength of the causal connection in your case, your jurisdiction, the overall litigation outcome, and the specific terms of any global settlement agreement. To discuss the potential value of your specific case, contact our team at 1 (855) 664-8713.

Recoverable damages in Depo-Provera claims typically include past and future medical expenses (surgery, radiation, follow-up care, medication), lost wages and diminished earning capacity, pain and suffering, emotional distress, loss of enjoyment of life, and in some cases, punitive damages if Pfizer’s conduct is found to have been especially egregious. You can also review our general settlement calculator for broader context on how mass tort settlements are calculated.

How to File a Depo-Provera Lawsuit in 2026

Filing a Depo-Provera claim in 2026 is a straightforward process when you work with an experienced mass tort attorney. Here is a step-by-step overview of what to expect:

1. Free Case Evaluation (Day 1): Call 1 (855) 664-8713 or complete an online intake form. A case specialist will review your Depo-Provera usage history and your meningioma diagnosis to determine whether you likely qualify for the litigation.
2. Attorney Matching (Days 1–3): If your case appears viable, you will be connected with a mass tort attorney who handles Depo-Provera cases. These attorneys work on a contingency fee basis — meaning you pay nothing unless and until you receive compensation.
3. Medical Records Collection (Weeks 1–4): Your attorney will gather your Depo-Provera prescription and administration records, imaging studies (MRI/CT scans), surgical and pathology reports, and any other medical documentation relevant to your diagnosis and treatment.
4. Complaint Filed (Weeks 4–8): Your attorney will prepare and file a formal complaint in federal court. Your case will be transferred to MDL 3140 in the Southern District of New York, where it will be consolidated with thousands of similar claims.
5. Discovery Phase (Months 2–18+): Both sides exchange documents and conduct depositions. In an MDL, much of this discovery is done at the consolidated level, so individual plaintiffs typically do not need to be deposed.
6. Settlement Negotiations or Trial: Once bellwether trials begin providing verdict data, global settlement negotiations typically accelerate. If a settlement is reached, your attorney will present you with the terms and advise you on whether to accept.

Use Our Free Depo-Provera Settlement Calculator

To get an estimate of what your claim may be worth, visit the Depo-Provera settlement calculator. Simply enter information about your treatment history, duration of Depo-Provera use, and injury severity to receive a personalized estimate based on comparable mass tort settlements.

MDL 3140 Case Status and Timeline

MDL 3140 — In Re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation — is currently pending before the Honorable Mary Kay Vyskocil in the U.S. District Court for the Southern District of New York. Here is the current status as of May 2026:

Total Cases Filed: Approximately 3,790 individual cases are currently pending in MDL 3140, with new cases being added weekly. Legal analysts expect the total case count to exceed 5,000 before any global settlement is reached.

Daubert Briefing: Fully briefed as of March 2026. The court is expected to issue rulings on plaintiffs’ and defendants’ respective Daubert motions by summer 2026. These rulings will determine which expert witnesses can testify at trial.

Bellwether Selection: The parties have submitted lists of potential bellwether trial candidates. If Daubert rulings favor plaintiffs, bellwether trials could begin as early as late 2026 or early 2027.

Settlement Prospects: Pfizer has not publicly committed to a settlement fund, but legal analysts note that the company’s exposure is substantial given the size of the MDL and the strength of the scientific evidence. Comparable pharmaceutical MDLs — such as the Hair Relaxer MDL and the Paraquat MDL — suggest that global settlements typically emerge 3–5 years after MDL formation, placing Depo-Provera squarely in the settlement window.

If you used Depo-Provera and developed a meningioma, it is critical that you file your claim as soon as possible. Statutes of limitations in most states run 2–3 years from the date you discovered (or should have discovered) the connection between your drug use and your injury. The clock is ticking. Contact us at 1 (855) 664-8713 to get started today.

Frequently Asked Questions: Depo-Provera Lawsuit 2026

About the Author

Mason Arnao is the President and Managing Partner of Waypoint Software, LLC — a leading U.S. software development and digital advocacy firm based in South Florida. With over 20 years of experience in data systems, technology infrastructure, and digital research, Mason has developed deep expertise in how pharmaceutical failures like the Depo-Provera meningioma litigation affect everyday people navigating complex legal systems. As publisher of TortAdvisor.com, Mason is committed to connecting injured victims with the information and legal resources they need to take action.